Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503396 | 0.85 | — | — | |
| SCHEMBL8679785 | 0.85 | ALDH1A1 (1.00) | ALDH1A1TSHRTDP1 | |
| SCHEMBL6223 | 0.85 | — | — | |
| Pyridine SCHEMBL19743133 | 0.80 | TSHR (0.53) | ALDH1A1TSHRTDP1 | |
| Water SCHEMBL10335432 | 0.80 | — | — | |
| SCHEMBL3662439 | 0.80 | — | — | |
| Methane SCHEMBL5413858 | 0.80 | — | — | |
| SCHEMBL3366971 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL3840624 | 0.80 | — | — | |
| SCHEMBL3664027 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891188-A4 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | PHERIN PHARM INC (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-0914165-A4 | STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF PMS AND ANXIETY | PHERIN PHARM INC (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20020103391-A1 | Novel androstanes for inducing hypothalamic effects | BERLINER DAVID L (US) | 2002-08-01 | — | — | US | disclosed |
| US-6331534-B1 | ADMINISTERING EFFECTIVE AMOUNT OF STEROID WITHIN NASAL PASSAGE OF INDIVIDUAL SUCH THAT IT BINDS SPECIFICALLY TO RECEPTORS ON SURFACE OF NASAL NEUROEPITHELIAL CELLS IN VOMERONASAL ORGAN | PHERIN PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| US-6117860-A | NASALLY ADMINISTERING STEROID WHICH BINDS TO A SPECIFIC NEUROEPITHELIAL RECEPTOR FOR ALLEVIATING PREMENSTRUAL TENSION AND ANXIETY | PHERIN PHARMACEUTICALS, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-6066627-A | ALTERING BLOOD CONCNETRATION OF LUTEINIZING HORMONE | PHERIN CORPORATION (US) | 2000-05-23 | — | — | US | disclosed |
| US-6057439-A | EPOXYSTEROIDS | PHERIN CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5969168-A | STIMULATE AUTONOMIC ACTIVITY | PHERIN CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| CN-1226837-A | Steroids as neurochemical stimulators of VNO to alleviate symptoms of PMS and anxiety | PHERIN CORP (US) | 1999-08-25 | — | — | CN | disclosed |
| EP-0914165-A1 | STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF PMS AND ANXIETY | Pherin Pharmaceuticals, Inc. (US) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998048811-A1 | METHOD OF FIXING FRAGRANCES IN FRAGRANCE COMPOSITION AND OTHER COMPOSITIONS | HUMAN PHEROMONE SCIENCES, INC. (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0783512-A4 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORP (US) | 1998-09-02 | — | — | EP | disclosed |
| WO-1998014194-A9 | STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF ANXIETY | — | 1998-08-27 | — | — | WO | disclosed |
| WO-1998003207-A9 | STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF PMS AND ANXIETY | — | 1998-05-22 | — | — | WO | disclosed |
| WO-1998014194-A1 | STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF ANXIETY | PHERIN PHARMACEUTICALS (US) | 1998-04-09 | — | — | WO | disclosed |
| WO-1998003207-A1 | STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF PMS AND ANXIETY | PHERIN PHARMACEUTICALS, INC. (US) | 1998-01-29 | — | — | WO | disclosed |
| WO-1997036596-A9 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | — | 1997-12-04 | — | — | WO | disclosed |
| WO-1997036596-A1 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | PHERIN PHARMACEUTICALS, INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| EP-0783512-A1 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORPORATION (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010031-A1 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORPORATION (US) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103391-A1 | Novel androstanes for inducing hypothalamic effects | FABP7, NR3C2, NR3C1 | ALDH1A1 2386/4885TSHR 141/4885TDP1 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.